Interferon - Novartis buys in hepatitis and depression drugs

Novartis buys in hepatitis and depression drugs
Reuters - ZURICH/LONDON (Reuters) - Novartis AG has boosted its pipeline by buying in rights to two new drugs, paying up to $525 million to U.S. biotech firm Idenix Pharmaceuticals Inc. for access to an experimental hepatitis C treatment. The Swiss drug maker

Relative risks of cirrhosis from non-alcoholic steatohepatitis
EurekAlert - Morbidity and mortality lower than for Hepatitis C, but still notable Cirrhosis related to non-alcoholic steatohepatitis (NASH) is associated with fewer complications and a lower mortality compared to cirrhosis from hepatitis C, despite NASH patients

Body parts scandal raises critical questions
Burlington Free Press - The list of Vermonters affected by a national scandal involving stolen body parts continues to grow, with three Vermont hospitals and three dental surgery facilities notified as recently as Monday of patients who might have received questionable

Hepatitis C Epidemic Vastly Underestimated By UK Government
Medical News Today - There are more than double the number of people infected with the hepatitis C virus (HCV) in England and Wales than the government has estimated, delegates at the British Society of Gastroenterology's Annual Scientific Meeting were warned. The

Chinese Patients With Chronic Hepatitis B Respond Better To
Medical News Today - Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) and Novartis (NYSE: NVS) today announced new data that demonstrate telbivudine, an investigational oral, once-daily nucleoside analogue, provided significantly greater antiviral and clinical efficacy in